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The author of the above mentioned paper have noticed a mistake in Table 1 following publication and wish to make the following correction.

The reference for the lapatinib study should be 36 (Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013;24:1931--6), and the reference for the 9-nitro-camptothecin study should be 43 (Chugh R, Dunn R, Zalupski MM, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005;23:3597--604).

The corrected Table [1](#Tab1){ref-type="table"} can be found below.Table 1Summary of systemic therapy dataTherapyTargetNumber of chordoma patientsReported resultsStudy designReferencesImatinibPDGFR501 PR (RECIST); 35 SD; median PFS = 9 months (RECIST)Single-arm phase II trialStacchiotti et al. \[32\]ImatinibPDGFR170 PR; 17 SDCase seriesFerraresi et al. \[33\]LapatinibEGFR1813 SD; 6 PR (Choi); 0 PR (RECIST); median PFS = 8 months (RECIST)Single-arm phase II trialStacchiotti et al. \[36\]ErlotinibEGFR11 PRCase reportSinghal et al. \[37\]Erlotinib + bevacizumabEGFR, VEGF33 SDCase reportAsklund et al. \[38\]Cetuximab + gefitinibEGFR11 PRCase reportHof et al. \[39\]Cetuximab + gefitinibEGFR11 PRCase reportLinden et al. \[40\]SorafenibMultiple271 PR (RECIST); 9-month PFS = 73.0%; 12-month OS = 86.5%Single-arm phase II trialBompas et al. \[41\]9-Nitro-camptothecinTopoisomerase I151 PR (RECIST); median PFS = 9.9 monthsSingle-arm phase II trialChugh et al. \[43\]ThalidomideMultiple11 PRCase reportChay et al. \[44\]GI-6301 (recombinant yeast-brachyury vaccine)Brachyury111 PR (RECIST); 1 mixed response (RECIST); median PFS = 8.3 monthsPhase I trialHeery et al. \[65\]Table is modified with permission from <http://www.chordomafoundation.org/systemic-therapy/>*PR* partial response, *PFS* progression-free survival, *RECIST* Response Evaluation Criteria in Solid Tumors, *SD* stable disease

The online version of the original article can be found under doi:10.1007/s40487-016-0016-0.
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